The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | Safety and efficacy of a CLDN18.2-specific CAR T-cell therapy in GI adenocarcinoma
Gregory P. Botta, MD, PhD, UC San Diego Medical Center, San Diego, CA, presents findings from a Phase I trial (NCT04404595) of a claudin 18.2 (CLDN18.2)-specific chimeric antigen receptor (CAR) T-cell therapy in patients with advanced gastric and pancreatic adenocarcinoma. The recruited patients typically have three or more lines of previous therapy and no treatment-related deaths were reported, with no gastritis or pancreatitis reported. A patient with gastric cancer had a complete response and disease control was observed in over half of patients with both forms of adenocarcinoma. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
